Exosomes; Nano-Scale Bubbles Creating Waves in Diagnostics and Therapeutics - Seite 3
Life Technologies Corp has created a mini documentary series entitled 'Exosomes-The Next Small Thing'. "Exosomes are a very powerful way, a new way of how cells communicate long distance... They are powerful mediators that carry all the signaling and machinery necessary to change the behavior of the neighboring cells." http://www.lifetechnologies.com/ca/en/home/life-science/cell-analysis/exosomes/exosomes-documentary-episode-1.html
PDF for Exosomes Market Snapshot: Enal Razvi, Ph.D.
http://www.genengnews.com/media/pdf/GEN-Biomarket-Trends-Report-Exosomes%20Market-Landscape-2013.pdf
Bio for Enal Razvi, Ph.D- Biotechnology Analyst and Managing Director of SelectBio U.S
Enal Razvi, Ph.D., conducted his doctoral work on viral
immunology and subsequent to receiving his Ph.D. went on to the Rockefeller University in New York to serve as Aaron Diamond Post-doctoral fellow under Professor Ralph Steinman [Nobel Prize Winner
in 2011 for his discovery of dendritic cells in the early-70s with Zanvil Cohn]. Subsequently, Dr. Razvi completed his research fellowship at Harvard Medical School. For the last two decades Dr.
Razvi has worked with small and large companies and consulted for more than 100 clients worldwide. He currently serves as Biotechnology Analyst and Managing Director of SelectBio U.S. He can be
reached at enal@selectbio.us
About Aethlon Medical, Inc.
Lesen Sie auch
Aethlon Medical creates innovative medical devices to address life-threatening diseases. The Aethlon ADAPT™ (Adaptive Dialysis-like Affinity Platform Technology) establishes the basis for a new class of therapeutics that target the rapid elimination of disease enabling particles from the circulatory system of treated patients. The lead Aethlon ADAPT™ product is the Hemopurifier®, a device that addresses a broad-spectrum of viral pathogens as well as tumor-secreted exosomes that suppress the immune system of cancer patients. Aethlon is also operating under two government contracts with the Defense Advanced Research Projects Agency (DARPA) related the development of a medical device to reduce the incidence of sepsis. Exosome Sciences, Inc. is a majority owned Aethlon subsidiary that is advancing exosome-based strategies to diagnose and monitor cancer and infectious disease progression. Additional information can be found at www.AethlonMedical.com